Remove 2008 Remove Biosimilars Remove Vaccines
article thumbnail

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

Pharmacy Times

Eligible patients include adults (≥ 18 years) diagnosed with CML receiving imatinib as first-line therapy for more than 1 month between 2008 and 2023. Materials and Methods This retrospective observational study utilized the Carolina Data Warehouse for Health electronic health record (EHR) database.

Dosage 26
article thumbnail

Beating the Big C

Pharmaceutical Technology

The world’s biggest pharmaceutical company Pfizer announced in June 2008 that it would be putting its “full scope and scale” behind a push into the cancer market. “Companies used to be universally protected by patents but there is a pathway to approval opening up for biosimilar legislation. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

PharmaShots

In 2008, Johnson acquired tissue sealing system developer, SurgRx Pfizer's pharmaceutical segment revenue increased after the acquisitions of Serenex, Encysive Pharmaceuticals, CovX, and Coley Pharmaceuticals Novartis reported a total revenue of $41.4B, under which, its pharmaceutical division faced a revenue loss of $2.6B

article thumbnail

The Future for Biotesting

Pharmaceutical Technology

Secondly, we conduct pre-clinical research and development in the fields of oncology, cardiovascular disorders, anti-influenza vaccines and diabetology. It will most probably lead to a new anti-flu vaccine. Biotest will be exhibiting at CPhI Worldwide 2008 between 30 September and 2 October, Messe Frankfurt, Germany.

article thumbnail

FDA-Approved Labeling: Is Enough Enough?

FDA Law Blog: Biosimilars

Things got so bad that Congress acted to shield vaccine manufacturers from liability in order to ensure sufficient availability of vaccines. The same considerations ring true for OTC drugs. FDA, for years, has been concerned with overwarning. billion in damages were brought between 1980 and 1986.

article thumbnail

ASBM’s Comments on the Medicare Drug Price Negotiation Plan: Protecting Patients and Ensuring Access to Medicines

Safe Biologics

Having served in the Department of Health and Human Services’ Office of the Secretary from 2002-2008, including two years as Associate Deputy HHS Secretary, I participated in the development and implementation of Medicare Part D, the program’s prescription drug benefit. In the meantime, I encourage you to read our comments here. [1]

article thumbnail

ASBM’s Comments on the Medicare Drug Price Negotiation Plan: Protecting Patients and Ensuring Access to Medicines

Safe Biologics

Having served in the Department of Health and Human Services’ Office of the Secretary from 2002-2008, including two years as Associate Deputy HHS Secretary, I participated in the development and implementation of Medicare Part D, the program’s prescription drug benefit. In the meantime, I encourage you to read our comments here. [1]